TRIUMPH Seminar, Cambridge, MA – September 24, 2015

Transporter Research in Drug Development – An Industry Perspective

Thursday, September 24th, 2015 – 9:30 AM– 3:00 PM EST
Le Méridien Cambridge-MIT | 20 Sidney Street, Cambridge, MA

REGISTER HERE using our contact form or email Rachel Whisnant at rwhisnant@optiviabio.com.

Talk Titles & Speakers:

DallasMODERATOR: Dallas Bednarczyk, Ph.D., Investigator, Novartis

Dr. Dallas Bednarczyk has been in the transporter field for more than 10 years working in academic environments, at contract research organizations, and in the pharmaceutical industry.  He has investigated aspects of transporter-mediated absorption, distribution, and excretion of drugs, as well as drug-drug interactions involving transporters.  His current role at Novartis involves developing strategy around transporter issues and identifying and implementing suitable solutions to address project team needs regarding the transport of molecules.

 

StevenSteven Louie, Ph.D., Senior Scientist, Amgen
Transporter Strategy in Drug Discovery and Development

Steven is a Senior Scientist in the Department of Pharmacokinetics and Drug Metabolism at Amgen, now in Cambridge, MA.  He is a Midwest boy at heart and did his undergraduate work at the University of Minnesota (Minneapolis/St. Paul, MN) and his graduate work at the University of Iowa (Iowa City, IA). He is a transporter jockey who has been developing and implementing in vitro tools and assays to support drug discovery and development for the last 20 years.  He is the 2015 Chair-elect to the AAPS Drug Transport Focus Group (DTFG).  He has the honor of organizing the AAPS eLearning Transporter 101 Course and the 2018 AAPS Transporter Workshop-From Benchside to Bedside.  Prior to joining Amgen, Steven worked at the VA Medical Center, University of Pennsylvania, Merck, and SmithKline Beecham (now GSK). Steven has worked on multiple transporters from multiple species including P-glycoprotein, BCRP, OATPs and OATs. His recent research interests include in vitro/in vivo extrapolation to predict transporter-mediated drug-drug interactions. Drugs that he has work on that have recently achieved IND-filing, FDA and/or EMA approvals include cinacalcet, omecamtiv mecarbil, velcalcetide, and carfilzomib.

PatrickPatrick Poulin, Ph.D., Consultant and Associate Professor, School of Public Health, Université de Montréal
The Suspected Role of Extracellular Binding Proteins in ADME/PD Research

Patrick Poulin has extensive experiences in toxicology and pharmacology aspects in drug development. Patrick’s has obtained a MSc and PhD degree in toxicology and pharmacology at the University of Montréal as well as a post-doctoral degree in pharmaceutical research at Roche Pharma Ltd. in Basel, Switzerland. Since 13 years Patrick’s is acting as an independent consultant for large pharmaceutical companies and small biotechs to conduct researches in PBPK/PD modeling and tissue distribution. He is also an associate professor at the University of Montréal (School of Public Health). Furthermore, Patrick’s is currently on the scientific advisory board of Aegis Technologies Inc., which develops commercially-available PBPK simulation softwares for the toxicologists and pharmacologists. Patrick’s is publishing several scientific manuscripts and book chapters; Patrick’s is the coauthor of a new book on toxicology: Drug Discovery Toxicology Book: From Target Assessment to Translational Biomarkers. Eight manuscripts were honoured as best publication of the years by the American Pharmacists Association. Finally, Patrick’s is also an active reviewer for several peer review journals.

AymanAyman El-Kattan, Ph.D., Associate Research Fellow, Pfizer
Predicting Human Clearance Mechanism of NMEs Using In Vitro Permeability and Compound Ionization: Application of Extended Clearance Classification System (ECCS) in Drug Discovery

Dr. Ayman El-Kattan is Associate Research Fellow at the Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Inc. Cambridge Laboratories. He earned his bachelor degree in pharmacy with distinction from University of Jordan and a Ph.D. in Basic Pharmaceutical Sciences at University of South Carolina in the US. His main research interests are focused on understanding the role of transporters in influencing drug disposition and oral absorption. Also, it involves studying the utility of physiological based pharmacokinetic modeling (PBPK) tools in projecting drug disposition and drug-drug interaction liabilities in man for new molecular entities (NME). He is also an Adjunct Professor at College of Pharmacy-University of Rhode Island in Rhode Island, US where he lectures in the graduate-level pharmacokinetic courses and serves as external advisor on dissertation committees. Dr. El-Kattan is active member of the American Association of Pharmaceutical Scientists (AAPS) and serves on the executive committee of the AAPS Northeast Regional Discussion Group – NERDG and Drug Transporter focus group. He has been invited speaker over 50 times at national and international conferences and meetings and has published over 100 papers in peer-reviewed Journals, book chapters and proceedings.

 

MeegahnMeeghan O’Connor, MA, Scientist III, Boehringer Ingelheim
Breast Cancer Resistance Protein: Insight into a Clinical Study Design to Investigate Drug-Drug Interactions

Meeghan O’Connor is a Scientist III in the department of Drug Metabolism and Pharmacokinetics at Boehringer Ingelheim Pharmaceuticals in Ridgefield, CT.  Meeghan received her B.S. degree in Forensic Science and Chemistry from the University of New Haven.  She then earned her M.S. in Pharmacology and Toxicology from the University of Connecticut.  At UConn Meeghan studied with Dr. José Manautou, and her thesis project involved the identification of differentially expressed genes in a model of acetaminophen autoprotection.  Meeghan previously presented her thesis work at a Northeast Society of Toxicology annual meeting, and has presented posters at various scientific meetings, including the Gordon Research Conference and multiple Society of Toxicology meetings.  Meeghan also received first place in a poster session held at the Northeast Society of Toxicology meeting.  Prior to joining Boehringer Ingelheim, she worked at Illumina as a Research Associate.  At Boehringer Ingelheim, Meeghan is responsible for the design and validation of drug transporter assays to support development projects.

Concluding with speaker panel and Q&A session

TRIUMPH strives to facilitate transporter information exchange, support collaborative research and promote increased recognition and broader utility of transporter research in drug discovery and development.